Hepatitis infection in haemodialysis patients
Version of Record online: 28 JUN 2008
Volume 7, Issue 3, pages 101–109, June 2002
How to Cite
HUANG, C.-C. (2002), Hepatitis infection in haemodialysis patients. Nephrology, 7: 101–109. doi: 10.1046/j.1440-1797.2002.00105.x
- Issue online: 28 JUN 2008
- Version of Record online: 28 JUN 2008
- Accepted for publication 26 November 2001.
- hepatitis B;
- hepatitis C;
- hepatitis G;
- TT virus
SUMMARY: Known hepatitis infections among haemodialysis patients include hepatitis B, hepatitis C, hepatitis G and TT virus. Haemodialysis patients with hepatitis B and/or hepatitis C infection may progress to develop significant morbidity, such as cirrhosis, hepatitic failure or hepatocellular carcinoma. Hepatitis B infection may be treated with α-interferon or lamivudine. Hepatitis C infection may be treated with α-interferon, but frequent severe adverse effects were observed, while ribavirin is contraindicated for patients with renal failure. Treatment for hepatitis B and/or hepatitis C are costly, and the risk of post-transplant reactivation of hepatitis has been reported. Prevention of nosocomial transmission of hepatitis infection with strict infection control and universal precautions is more important. Accumulating evidence suggests that both hepatitis G virus and TT virus (TTV) are not significant causes of liver disease. Routine screening for hepatitis G or TTV viraemia in haemodialysis patients is not indicated at present.